Drugs News and Research

RSS

Lysosomal-immune axis associated with COVID-19 severity

New research suggests the modulation of lysosomal-immune pathways may present a novel drug-targeting strategy to attenuate SARS-CoV-2 infections.

2 Feb 2021

Gene mutations may explain the poorer outcomes in Hispanic and Latino children with leukemia

A combination of genetic mutations may explain the higher incidence of and poorer outcomes from pediatric leukemia in Hispanic and Latino children, according to Penn State College of Medicine researchers.

2 Feb 2021

Remyelinating drug shows potential to improve vision in patients with MS

A team led by a biomedical scientist at the University of California, Riverside, reports a drug -- an estrogen receptor ligand called indazole chloride (IndCl) -- has the potential to improve vision in patients with multiple sclerosis, or MS.

2 Feb 2021

Breast cancer‐on‐a‐chip to test the effectiveness of checkpoint inhibitor drugs

There are many mechanisms by which the body responds to foreign invaders. One of these involves the T-cells of the immune system, which have a number of different proteins on their surface called "checkpoint proteins."

2 Feb 2021

Yale scientists develop an injection-based therapy for skin cancer

Yale researchers are developing a skin cancer treatment that involves injecting nanoparticles into the tumor, killing cancer cells with a two-pronged approach, as a potential alternative to surgery.

2 Feb 2021

Study finds increased opioid consumption two years after intensive care

Nearly 11 percent of people admitted to an intensive care unit in Sweden between 2010 and 2018 received opioid prescriptions on a regular basis for at least six months and up to two years after discharge.

2 Feb 2021

Scientists discover potential drug target for Hutchinson-Gilford progeria syndrome

New study describes a potential drug target for Hutchinson-Gilford progeria syndrome that may aid in the development of more effective treatments.

2 Feb 2021

Study shows safety and effectiveness of two recommended ICU sedatives

Sedative medications used in intensive care are associated with increased delirium, which is in turn connected with higher medical costs and greater risk of death and ICU-related dementia.

2 Feb 2021

Zinc supplementation bolsters repurposed antivirals against SARS-CoV-2

A new preprint reports the efficacy of two repurposed drugs that could be useful against SARS-CoV-2 when supplemented with zinc.

2 Feb 2021

ACE2 agonist C21 relieves respiratory difficulty in COVID-19

A new study describes a pilot study on the efficacy of a molecule called C21, which enhances the activity of the angiotensin-converting enzyme 2 (ACE2), the host cell receptor that facilitates viral entry.

2 Feb 2021

Antiviral compound GC-376 shows efficacy against SARS-CoV-2 in vivo

Over the past months, many potential antivirals against SARS-CoV-2 have been identified as deserving further development to target several viral proteins. A new study deals with one such molecule, the viral main protease (Mpro) inhibitor GC-376, and describes its efficacy in inhibiting virus-host interaction.

2 Feb 2021

Albumedix submits Drug Master Files for its products in Japan

Albumedix Ltd. (‘Albumedix’), the world leader in recombinant human albumin (rHA), announced today the submission of Drug Master Files (DMFs) to the Pharmaceutical and Medical Device Agency (PMDA) in Japan.

From Albumedix Ltd. 2 Feb 2021

Albumedix enters into collaboration agreement with Cell and Gene Therapy Catapult

Albumedix Ltd. (‘Albumedix’), an enabler of advanced therapies and the world leader in recombinant human albumin (rAlb), announced today that they have entered into a collaboration agreement with Cell and Gene Therapy Catapult (CGT Catapult) to investigate the use of Albumedix´ proprietary albumin-based solutions for advanced therapy applications, including viral vectors manufacturing.

From Albumedix Ltd. 2 Feb 2021

Prostate drug may have potential to prevent or delay the development of Parkinson's disease

Taking a particular type of medication to treat enlarged prostate is associated with a reduced risk of developing Parkinson's disease, according to a large observational study led by researchers at the University of Iowa, with colleagues in Denmark and China.

1 Feb 2021

Increased access to testing, treatment has reduced hepatitis C in low- and middle-income countries

Many low- and middle-income countries have reduced suffering from hepatitis C, thanks to increased access to testing and treatment.

1 Feb 2021

WHO revises definition of extensively drug-resistant tuberculosis

The definition of extensively drug-resistant tuberculosis (XDR-TB) has been revised by the World Health Organization's Global TB Programme, who have also defined pre-XDR-TB for the first time, highlighting the seriousness of these forms of TB.

1 Feb 2021

An integrated approach could pave the way for future control of Alzheimer's disease

This new pioneering study by Prof. Ricardo Maccioni and coworkers of the International Center for Biomedicine, "New Frontiers in the prevention, diagnosis and treatment of Alzheimer´s disease" was published in the special issue of Latin American investigators of the Journal of Alzheimer's Disease.

1 Feb 2021

CU Boulder research offers clues to why psychiatric drugs help only some people

New CU Boulder research, published in the journal eLIfe, sheds light on one reason those individual differences may exist. Turns out a key protein in the brain called AKT may function differently in males than females.

1 Feb 2021

NYU Dentistry researcher receives NIH grant to study mitochondrial permeability transition

The National Institute of General Medical Sciences, part of the National Institutes of Health, has awarded NYU College of Dentistry's Evgeny Pavlov a grant to study a phenomenon called mitochondrial permeability transition, one of the central causes of tissue damage during stroke and heart attack.

1 Feb 2021

Study uncovers new anti-inflammatory role for blood clot protein fibrinogen

Flinders University researchers have discovered a new anti-inflammatory role for well-known blood clot protein fibrinogen, which could support targeted new treatments for kidney, heart and other common diseases.

1 Feb 2021